Literature DB >> 23888214

Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis.

Josef Finsterer1, Claudia Stöllberger, Gabor G Kovacs.   

Abstract

Sporadic inclusion body myositis (sIBM) usually manifests with painless weakness of the hand, finger and hip flexors. Absence of symptoms or signs, but mild hyper-CK-emia as the sole manifestation of IBM, has not been reported. We report the case of a 73-year-old male who presented with asymptomatic recurrent hyper-CK-emia ranging from 200 to 1324U/L (n<171U/L), since 10 years. Clinical neurologic investigation, nerve conduction studies and EMG were non-informative. Muscle biopsy surprisingly revealed sIBM. sIBM may be asymptomatic and may manifest with hyper-CK-emia exclusively. So, it has to be included in the differential diagnoses of asymptomatic hyper-CK-emia.

Entities:  

Keywords:  cardiomyopathy; creatine-kinase; muscle biopsy; myositis; neuromuscular disorder

Year:  2013        PMID: 23888214      PMCID: PMC3718245          DOI: 10.4081/ni.2013.e11

Source DB:  PubMed          Journal:  Neurol Int        ISSN: 2035-8385


Introduction

Clinical presentation of sporadic inclusion body myositis (sIBM) is variable, but most frequently characterized by painless weakness of the hand, fingers and hip flexors.[1] Creatinekinase (CK) is only mildly elevated in sIBM.[1] Absence of symptoms and signs but mild hyper-CK-emia as the sole manifestation of sIBM has not been reported.

Materials and Methods

For assessment of the muscle biopsy routine stainings on frozen sections (hematoxylin and eosin, Gomori-trichrome, PAS, Oil-red-O), enzymehistochemistry (COX/SDH, NADH, ATPase pH 4,2), immunohistochemistry (slow and fast myosin, utrophin-NT, dystrophin and associated proteins, NCAM, vimentin, desmin), a panel of so-called nonsense proteins and neurofilament (SMI-31), and inflammatory markers were performed. The list of antibodies used is detailed in Table 1. We examined in sum nine semithin sections and two were selected for electron microscopy using a Zeiss EM 109 Turbo/DPS (Carl Zeiss Inc., Thornwood, NY, USA).
Table 1.

List of antibodies applied during the histological work-up of the muscle biopsy. Positivity was found for antibodies against CD3, CD8, CD68, NCAM, p62, and SMI31.

AntibodySection typeCompanyDilutionClonality
Alpha-B-crystallinFrozenNovocastra1:250Mono
Alpha-sarcoglycanFrozenNovocastra1:200Mono
Amyloid precursor proteinParaffinChemicon1:8000Mono
Amyloid precursor proteinFrozenChemicon1:8000Mono
Amyloid-beta (b-A4)ParaffinDako1:100Mono
Amyloid-beta (b-A4)FrozenDako1:100Mono
Beta-sarcoglycanFrozenNovocastra1:200Mono
c5b-9FrozenDako1:4000Mono
CaveolinFrozenSanta Cruz1:200Mono
CD20FrozenDako1:2000Mono
CD3FrozenNeomarkers1:200Mono
CD4FrozenDako1:100Mono
CD68FrozenDako1:10000Mono
CD79aFrozenDako1:200Mono
CD8FrozenDako1:400Mono
DesminParaffinDako1:50Mono
DesminFrozenDako1:50Mono
DysferlinFrozenNovocastra1:10Mono
Dystrophin 1FrozenNovocastra1:20Mono
Dystrophin 2FrozenNovocastra1:20Mono
Dystrophin 3FrozenNovocastra1:20Mono
Delta-sarcoglycanFrozennovocastra1:50Mono
EmerinFrozenNovocastra1:100Mono
Gamma-sarcoglycanFrozenNovocastra1:200Mono
HLA-ABCFrozenDako1:8000Mono
Leukocyte common antigenParaffinDako1:2000Mono
Leukocyte common antigenFrozenDako1:2000Mono
MerosinFrozenNovocastra1:100Mono
Myosin fastFrozenNovocastra1:100Mono
Myosin slowFrozenNovocastra1:100Mono
NCAMFrozenMonosan1:20Mono
p62ParaffinBD1:500Mono
p62FrozenBD1:500Mono
PrP3F4cParaffinSignet1:100Mono
PrP3F4cFrozenSignet1:1000Mono
SMI31ParaffinSternberger1:1000Mono

Results

The patient is a 73-year-old Caucasian male, with a previous history of left bundle-branchblock since age 64 years, recurrent hyper-CK-emia since a border-zone stroke at age 64 ranging between 200 and 1324 U/L (n<171 U/L), hyperlipidemia since age 64 years requiring statin therapy after detection of hyper-CK-emia, ischemic left posterior borderzone stroke at age 72, a 60% stenosis of the left internal carotid artery, and arterial hypertension since age 72. The family history was negative for neuromuscular disorder (NMD). Clinical neurologic examination revealed positional tremor exclusively. CK was 603 U/L. There was mild hypercholesterolemia. Nerve conduction studies and needle electromyography of the right brachial biceps and right gastrocnemius muscles were non-informative. CK remained elevated even after discontinuation of simvastatin. Muscle biopsy from the right lateral vastus muscle was strongly indicative of IBM (Figure 1). The most obvious muscle pathological alterations were the caliber changes with atrophic fibers (Figure 1A) and many rimmed vacuoles together with endomysial inflammatory infiltrates (Figure 1B and C). In addition, COX negative-fibers (Figure 1D) and a single ragged-red fiber (RRF) and rimmed-vacuoles (Figure 1E and F) were noted in the Gomoritrichrome staining. The inflammatory infiltrates consisted mainly of CD3-positive T-cells, including CD8-positive cytotoxic T-cells with invasion of intact muscle fibers (Figure 1G, H). There were only single B-cells and only a few CD68-immunoreactive monocyte/macrophages. HLA-class I antigen was only focally and weakly upregulated and there was no evidence for the deposition of terminal complement complex (C5b9) in capillaries. Furthermore, there were no necrotic fibers or perifascicular atrophy. SMI-31 (neurofilament) and p62 (Figure 1I) showed immunoreactivity in the vacuoles. Dystrophin and associated proteins (Table 1) did not show alterations and there was a lack of accumulation of desmin (Figure 1J). We noted signs of a neurogenic muscle lesion with groups of atrophic fibers, upregulation of NCAM (Figure 1K) without corresponding vimentin immunoreactivity, and decreased central activity of NADH without typical targets (Figure 1L). Ultrastructural examination revealed fibers with autophagic vacuoles with sequestered cytoplasmic organelles and degradation products (Figure 1M-O). Typical tubulofilamentous inclusions were not detected. In summary, according to the presence of i) invasion of non-necrotic fibers by mononuclear cells, ii) vacuolated muscle fibers, iii) SMI-31 and p62/ubiquitin immunoreactivity of inclusions and vacuoles, IBM was diagnosed. Since there is no established therapy available for sporadic IBM and since symptoms and signs were absent, no specific neurological treatment was introduced.
Figure 1.

Muscle biopsy from the right lateral vastus muscle showing atrophic fibers with caliber changes (A), many rimmed vacuoles together with endomysial inflammatory infiltrates (B, C), COX negative-fibers (D) and a single RRF with rimmed-vacuoles (E, F). Inflammatory infiltrates consisted mainly of CD3-positive T-cells, including CD8-positive cytotoxic T-cells with invasion of intact muscle fibers (G, H). SMI-31 (neurofilament) and p62 (I) showed immunoreactivity in the vacuoles. Signs of a neurogenic muscle lesion with fiber-type grouping and upregulation of NCAM were noted (K). Ultrastructural examination revealed fibers with autophagic vacuoles with sequestered cytoplasmic organelles and degradation products (M, N, O).

Discussion and Conclusions

The presented patient is interesting for hyper-CK-emia as the sole manifestation of IBM, a poorly understood progressive muscle disease of middle or late life. Contrary to the classical clinical presentation with weakness of the proximal leg and distal arm muscles in an asymmetric distribution,[1] our patient presented only with hyper-CK-emia but had not developed muscle weakness so far. In the majority of the cases, sIBM manifests already at onset with muscle weakness of the proximal and distal arm and leg muscles.[2] Causes of asymptomatic hyper-CK-emia other than sIBM include calpainopathy, dysferlinopathy, central core disease, multicore disease, McArdle’s disease, metabolic myopathy, polymyositis, sarcoid myopathy, endocrine myopathy, statin myopathy, and rhabdomyolysis.[3-5] These differentials were excluded in the presented patient by musclce biopsy and other blood chemical values. Weakness in sIBM predominantly affects the finger flexors, the wrist flexors, or the quadriceps muscle. sIBM has a dual pathology of autoimmunity and unexplained myofiber degeneration or loss of myofibers.[6] The diagnosis is established by muscle biopsy showing the typical features of invasion of non-necrotic fibers by mononuclear cells, vacuolated muscle fibers, and either intracellular amyloid deposits or tubulofilaments 15-18 nm in diameter on electron microscopy.[6] Contrary to sIBM hereditary inclusion body myopathy (hIBM) may initially affect the quadriceps muscle and may follow an autosomal dominant trait of inheritance,[7] may spare the quadriceps muscle but may follow an autosomal dominant transmission,[8] may manifest as distal myopathy Nonaka,[9] may be associated with Paget’s disease and fronto-temporal dementia,[10] or may be linked to the myosin-heavy chain-II locus.[11] Patients with hIBM are usually younger than patients with sIBM, are virtually always symptomatic, and there is no inflammation in their biopsies. No reliable effective therapy is currently available, neither for sIBM nor for hIBM.[7] The reason why sIBM in the presented patient manifested only with hyper-CK-emia remains speculative but could be explained by a new mutation in one of the genes associated with hIBM. Recently it has been shown that ageing may have an influence on the development of sIBM.[12] This case shows that sIBM may be asymptomatic and may manifest with hyper-CK-emia exclusively. sIBM has to be included in the differential diagnoses of asymptomatic hyper-CK-emia.
  12 in total

Review 1.  Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies.

Authors:  Marinos C Dalakas
Journal:  Nat Clin Pract Neurol       Date:  2006-08

Review 2.  Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Lancet Neurol       Date:  2007-07       Impact factor: 44.182

Review 3.  Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis.

Authors:  Valerie Askanas; W King Engel; Anna Nogalska
Journal:  J Neuropathol Exp Neurol       Date:  2012-08       Impact factor: 3.685

4.  Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin.

Authors:  Christoph Schindler; Marcus Thorns; Klaus Matschke; Sems Malte Tugtekin; Wilhelm Kirch
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

5.  Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene.

Authors:  D Haubenberger; R E Bittner; S Rauch-Shorny; F Zimprich; C Mannhalter; L Wagner; I Mineva; K Vass; E Auff; A Zimprich
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

6.  Asymptomatic hyper-CK-emia: an electrophysiologic and histopathologic study.

Authors:  J L Joy; S J Oh
Journal:  Muscle Nerve       Date:  1989-03       Impact factor: 3.217

7.  Vacuolar myopathy sparing the quadriceps.

Authors:  M Sadeh; N Gadoth; H Hadar; E Ben-David
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

Review 8.  Genetics of inclusion-body myositis.

Authors:  M Needham; F L Mastaglia; M J Garlepp
Journal:  Muscle Nerve       Date:  2007-05       Impact factor: 3.217

Review 9.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Semin Neurol       Date:  2012-11-01       Impact factor: 3.420

Review 10.  Pathogenesis and therapy of inclusion body myositis.

Authors:  Steven A Greenberg
Journal:  Curr Opin Neurol       Date:  2012-10       Impact factor: 5.710

View more
  4 in total

Review 1.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

Review 2.  Inclusion body myositis.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 3.  Inclusion body myositis: Update on the diagnostic and therapeutic landscape.

Authors:  Elie Naddaf
Journal:  Front Neurol       Date:  2022-09-27       Impact factor: 4.086

4.  The Anion Gap is a Predictive Clinical Marker for Death in Patients with Acute Pesticide Intoxication.

Authors:  Sun-Hyo Lee; Samel Park; Jung-Won Lee; Il-Woong Hwang; Hyung-Jun Moon; Ki-Hwan Kim; Su-Yeon Park; Hyo-Wook Gil; Sae-Yong Hong
Journal:  J Korean Med Sci       Date:  2016-05-09       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.